Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | NRP1 | O14786 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.42 |
| ▸ | CALCR | P30988 | 2/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194515 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL21043608 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL1247799 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL7263725 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL1247795 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12261069 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL13084631 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL14227389 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12899266 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12237919 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |